featured
Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
J. Clin. Oncol 2013 Jul 01;[EPub Ahead of Print], M Dowsett, I Sestak, E Lopez-Knowles, K Sidhu, AK Dunbier, JS Cowens, S Ferree, J Storhoff, C Schaper, J CuzickFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.